Skip to main content
. Author manuscript; available in PMC: 2012 Jan 18.
Published in final edited form as: Nat Neurosci. 2010 Sep 19;13(10):1265–1270. doi: 10.1038/nn.2632

Table 1.

In vitro and in vivo characterization of O-arylcarbamate FAAH inhibitors

graphic file with name nihms341209u1.jpg
Compound R IC50 (nM)a FAAH Inhibition in liver (%)b FAAH Inhibition in brain (%)b
1a (URB597) H 7.7 ± 1.5 Not determined 96.2 ± 0.4
1b (URB937) OH 26.8 ± 4.9 91.7 ± 0.7 −3.0 ± 8.0
1c OCH3 45.3 ± 14.1 94.6 ± 0.7 86.4 ± 2.1
1d CH3 20.5 ± 0.6 93.0 ± 1.1 91.9 ± 1.5
1e F 49.7 ± 5.8 90.7 ± 1.2 89.7 ± 1.3
1f NH2 42.5 ± 4.2 92.2 ± 0.6 23.2 ± 2.1
a

IC50 measured in membrane preparations of Wistar rat brain

b

FAAH inhibition measured ex vivo 1 h after injection in Swiss Webster mice (1 mg-kg−1, i.p., n = 3)